
Please try another search
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1 clinical trial for the treatment of solid tumors. It has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; collaboration and supply agreement with MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; and licensing agreement with CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Leonard Kruimer | 63 | 2018 | Independent Chairman of the Board |
Kristoffer Bissessar | 54 | 2020 | Independent Director |
Thomas O. Hecht | 71 | 2020 | Independent Director |
Vincent Ossipow | 56 | 2021 | Independent Director |
Rienk Offringa | - | 2017 | Member of Scientific Advisory Board |
Falk Nimmerjahn | - | 2017 | Member of Scientific Advisory Board |
Bernd Robert Seizinger | 68 | 2018 | Independent Director |
Alexander Maximiliaan Marie Eggermont | - | 2021 | Member of Scientific Advisory Board |
Mark Cragg | - | - | Member of Scientific Advisory Board |
Alexander Rudensky | - | 2017 | Member of Scientific Advisory Board |
Stephen Beers | - | - | Member of Scientific Advisory Board |
Natalie Brittenham Berner | 35 | 2022 | Independent Director |
Elin Birgersson | 40 | 2024 | Employee Representative Director |
Laura Lassouw-Polman | 46 | 2024 | Independent Director |
Nanna Luneborg | 50 | 2022 | Independent Director |
Tomas Wall | 44 | 2025 | Employee Representative Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review